BeOne Medicines, a global drug company that originated in mainland China, plans to launch more cancer drugs in Hong Kong and expand production in Guangzhou to tap greater market opportunities arising from local drug-approval reforms two years ago. The company has brought three types of cancer medications to Hong Kong so far and intends to seek approval from local health authorities to cover additional medical indications by the end of this year. “The Guangzhou facility, which now produces large…
You must log in or # to comment.